Neurotrope: Jumps on announcement of strategic review

NextTrip

08/10/2019 13:57

** Drug developer's shares  NTRP.O  rise 11% to 80 cents
premarket on strategic review
    ** Says review became important after its Alzheimer's drug
Bryostatin-1 failed a mid-stage study last month  urn:newsml:reuters.com:*:nL3N26030O
    ** Since the failed study, NTRP stock had lost ~84% as of
Monday
    ** Still determining how to proceed with current development
programs for Bryostatin-1 - NTRP  urn:newsml:reuters.com:*:nPn7MYgyqa
    ** Company did not specify alternatives it may consider but
said it has formed a strategic alternatives committee
    ** Stock was down ~80% YTD as of Monday

 (Reporting by Shariq Khan in Bengaluru)
 ((Shariq.Khan@thomsonreuters.com; Twitter: @s_qakhan))